Clinical Trials
Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD
Many of my colleagues and I are members of the Cross-Company Abuse Liability Council (CCALC), where I have been a co-chair for the past seven years, and a member for 15.
5 Red Flags That Show Your CRO Isn’t Giving You the Attention You Deserve
Choose a CRO Who Understands Your Worth
Like any good relationship, going steady with a CRO should be about mutual commitment, transparency, and shared goals. But what if your CRO isn’t giving you the time and effort you deserve?
Here are five red flags that show your CRO isn’t making you a priority—and how Altasciences guarantees the support you deserve.
-
You always have to ask for attention.
Are you constantly chasing updates or feeling like an afterthought? It might be time to rethink your partnership. At Altasciences, we believe in the type of commitment where you never have to wonder where you stand or compete with late-phase deliverables. With a dedicated, cross-functional team by your side, you’ll always be a priority. No mixed signals—just clear, proactive updates.
-
They keep changing plans on you.
You’ve agreed on dates, but they’re always running late or delaying your studies. At Altasciences, size and spend don’t matter; whether you place one study or a complete program with us, we stay true to our commitment to you. And if timeline changes are a possibility, we will be able to anticipate them and present solutions before they happen. Our customized roadmaps and centralized scheduling system facilitate active timeline management, real-time responses, and proactive communication; you’ll know what activities are taking place in real time.
-
They’re making you repeat yourself.
If you’re constantly repeating information, they’re not putting in the effort to make your relationship easier. Think of partnering with Altasciences like a honeymoon period that never ends. With our proprietary database, Ask Albert, we capture and share your preferences, study requirements, drug information, and results across all departments and phases. That way, you’ll only have to Tell Us Once™.
-
They’re hard to reach.
If they take eons to respond to your calls or emails, they might be giving you the runaround. At Altasciences, you’ll never feel ignored. With a central point of contact, the same program managers will stick with you for your entire journey with us. And if you ever need extra insight, our executive team is just a call away. No games—just a partner who’s always within reach.
-
They’re all talk.
Promises are great, but if your CRO keeps making commitments they can’t keep, it’s time to re-evaluate.
Altasciences won’t ghost you for the next big crush; you are our partner, not a simple transaction. We are a CRO/CDMO that’s fully committed to you and your project, and we believe in transparency, responsiveness, and the importance of being dependable and honest. You deserve nothing less.
Discover how Altasciences could be the right CRO for you:
VIDEO:The True Meaning of Moving in Unison
Ingrid Holmes, VP of Global Clinical Operations, and Lynne Le Sauteur, VP of Laboratory Sciences, discuss how the synergy between our clinical and bioanalytical teams drives our integrated solution.
BLOG: 4 Essential Topics to Cover in Your First CRO Meeting
Chad Rathlef, Executive Director of Strategic Partnerships, and Lisa Sanford, VP of Business Development, outline how to navigate this pivotal moment and set yourself up for a long-lasting partnership.
VIDEO: QUICK CHAT with Chris Perkin—One Operational Structure
Altasciences' CEO, Chris Perkin, discusses how our internal structure differs from other CROs and CDMOs, and how this addresses a major challenge within the industry and accelerates timelines for clients.
Discover the Art of Expert Formulation―From Concept to Clinic
Start Your Project Off on the Right Foot
Formulation development drives every phase of early drug development―from concept to clinic. It ensures precise dosing, drug stability, and safety while providing critical data for regulatory submissions.
This infographic shows how we design and optimize pharmaceutical formulations to maximize therapeutic benefits and ensure the safety of your clinical trials.
Do you have an active pharmaceutical ingredient (API) that needs to be formulated? Contact us today.
Related resources that may interest you:
- eBook: Achieving Optimal Formulation for Preclinical Testing
- eBook: Maximizing Drug Formulations for First-in-Human Trials
- Video: Key Steps in Complex and Customized Formulation Development
[VIDEO SERIES] Discover the Teams Behind Our Clinical Success
Think Altasciences
Watch our video series spotlighting our superb clinical facilities and the talented, dedicated teams in Montréal, Kansas, and Los Angeles. Learn more about who we are and what sets us apart in early-phase clinical development.
We hope you enjoy learning more about us!
You may also be interested in these resources:
- Webpage: Clinical Research Services
- eBook: Altasciences’ Facilities – Moving in Unison
Tailored Manufacturing and Analytical Testing for Your Molecules
A CDMO You Can Count On.
From discovery to commercialization, our manufacturing team is dedicated to delivering high-quality and FDA-compliant products, every time.
Discover our full range of drug development, manufacturing, and analytical testing services for oral solid dosage forms, injectables, creams, and gels―including the shipping and handling of highly potent compounds and controlled substances.
With over 25 years of experience, in-house R&D and formulation laboratories, innovative platforms and technology, and an exceptional team of scientists, we are committed to providing you with the best manufacturing solutions for your program.
You can count on us!
Speak with one of our experts today to get started.
Related resources that may interest you:
Inside The Altascientist: Understanding Drug Interaction Factors for Safer, More Effective Therapies
Intrinsic factors such as age, biological sex, comorbidities, or genetics can potentially alter drug exposure, as can extrinsic factors such as concomitant drugs, supplements, the environment, and food and beverages.
Case Study: How Altasciences Launched a Phase I Study 70% Faster Than the Industry Standard
Clinical trial start-up is a critical phase that carries many risks of delay, that can adversely impact the study timelines and budget. Altasciences was able to achieve an expedited project launch from the typical 12-week start-up process to just 3.5 weeks for a client by aligning our internal team on all objectives, engaging in open dialogue with the sponsor, and optimizing project management by assigning two project leads in two different time zones.
Case Study—Driving Simulator Assessment
How Combined CDMO and Clinical Teams Accelerate Drug Development
Streamlined Processes. Faster Approval.
In this new video, we share how our integrated teams’ combined expertise in clinical trials and manufacturing simplify the drug development process, empowering you to bring innovative therapies to market faster and, ultimately, improve patient outcomes.
Watch now to learn how our cohesive approach minimizes delays, reduces costs, and enhances collaboration.
Looking for drug development and manufacturing services? Speak with one of our experts today.
Related resources that may interest you:
- Webpage: Pharmaceutical Contract Manufacturing Services
- eBook: Advantages of Conducting Early-Phase Clinical Research in Canada
- Webinar: Overcoming Challenges in Manufacturing for Clinical Trials